Source: Investing.com ↗

Dyne Therapeutics stock faces pressure after rival drug fails trial

|

Translation unavailable. Please try again.

Original report

Read the original report on Investing.com ↗

Recommended markets

No specific asset was identified in this report; browse live USDT reference pairs.

Browse markets →

USDC/USDT

$1.00

-0.01%

BTC/USDT

$86,194.05

+0.80%

ETH/USDT

$2,744.86

+0.44%

ZEC/USDT

$1,626.71

+7.19%

XRP/USDT

$1.62

+6.02%